This piece gets in on big-money merit. Check out the Wall Street Journal for a quick story about Novartis and MorphoSys, a German biotech, expanding their collaboration -- to the tune of a 10-year, $600 million partnership. The alliance is geared toward "the discovery and development of antibody-based biological drugs," according to the article.